SG11201803760VA - Diamino pyridine derivatives - Google Patents
Diamino pyridine derivativesInfo
- Publication number
- SG11201803760VA SG11201803760VA SG11201803760VA SG11201803760VA SG11201803760VA SG 11201803760V A SG11201803760V A SG 11201803760VA SG 11201803760V A SG11201803760V A SG 11201803760VA SG 11201803760V A SG11201803760V A SG 11201803760VA SG 11201803760V A SG11201803760V A SG 11201803760VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- basel
- pct
- novartis
- pyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res:0) (43) International Publication Date .... ....r .....) 1 June 2017 (01.06.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/089985 Publication Al Number (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07D 401/12 (2006.01) A61P 35/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61K 31/444 (2006.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW SA, PCT/IB2016/057105 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 24 November 2016 (24.11.2016) ZW. (25) Filing Language: English (8 4 ) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 15196542.3 26 November 2015 (26.11.2015) EP TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 4056 Basel (CH). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor: THOMA, Gebhard; Novartis Pharma AG, No yards Institutes for Biomed. Research, 4002 Basel (CH). Declarations under Rule 4.17: (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel — as to applicant's entitlement to apply for and be granted a (CH). patent (Rule 4.170) (81) Designated States (unless otherwise indicated, for every Published: kind of national protection available): AE, AG, AL, AM, 21(3)) with international search report (Art AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, Il .4t In GC C\ C\ GC C::: , IN 1-1 (54) Title: DIAMINO PYRIDINE DERIVATIVES 0 N (57) : The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The ega ) present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15196542 | 2015-11-26 | ||
| PCT/IB2016/057105 WO2017089985A1 (en) | 2015-11-26 | 2016-11-24 | Diamino pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803760VA true SG11201803760VA (en) | 2018-06-28 |
Family
ID=54705130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803760VA SG11201803760VA (en) | 2015-11-26 | 2016-11-24 | Diamino pyridine derivatives |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10570096B2 (en) |
| EP (2) | EP3380465B1 (en) |
| JP (1) | JP6634157B2 (en) |
| KR (1) | KR102097878B1 (en) |
| CN (2) | CN108349937B (en) |
| AU (1) | AU2016359438B2 (en) |
| BR (1) | BR112018009540A2 (en) |
| CA (1) | CA3005159A1 (en) |
| CL (1) | CL2018001370A1 (en) |
| CO (1) | CO2018005354A2 (en) |
| CR (1) | CR20180285A (en) |
| CU (1) | CU24506B1 (en) |
| CY (1) | CY1123543T1 (en) |
| DK (1) | DK3380465T3 (en) |
| DO (1) | DOP2018000127A (en) |
| EA (1) | EA035899B1 (en) |
| EC (1) | ECSP18041731A (en) |
| ES (2) | ES2829052T3 (en) |
| HK (1) | HK1253530A1 (en) |
| HR (1) | HRP20201662T1 (en) |
| HU (1) | HUE052345T2 (en) |
| IL (1) | IL259360B (en) |
| LT (1) | LT3380465T (en) |
| MX (1) | MX2018006495A (en) |
| MY (1) | MY195905A (en) |
| PE (1) | PE20181071A1 (en) |
| PH (1) | PH12018501019A1 (en) |
| PL (2) | PL3757097T3 (en) |
| PT (2) | PT3380465T (en) |
| RS (1) | RS60946B1 (en) |
| RU (2) | RU2730007C2 (en) |
| SA (1) | SA518391657B1 (en) |
| SG (1) | SG11201803760VA (en) |
| SI (1) | SI3380465T1 (en) |
| WO (1) | WO2017089985A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035899B1 (en) * | 2015-11-26 | 2020-08-28 | Новартис Аг | Diamino pyridine derivatives as jak inhibitors |
| KR102630669B1 (en) | 2019-01-11 | 2024-01-30 | 노파르티스 아게 | LTA4H inhibitors for the treatment of hidradenitis suppurativa |
| TW202342048A (en) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | Methods of treating hidradenitis suppurativa using lou064 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (en) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Co-crystal pharmaceutical composition |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| MX2009006081A (en) * | 2006-12-08 | 2009-06-17 | Irmc Llc | Compounds and compositions as protein kinase inhibitors. |
| CA2681015C (en) | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2010058846A1 (en) * | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | 4,6-diaminonicotinamide compound |
| US8575153B2 (en) | 2008-11-28 | 2013-11-05 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| SG172885A1 (en) * | 2009-01-23 | 2011-08-29 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| EP2909174A1 (en) | 2012-10-19 | 2015-08-26 | F. Hoffmann-La Roche AG | Inhibitors of syk |
| AU2013341185B2 (en) * | 2012-11-08 | 2017-07-13 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses |
| MA38072A1 (en) | 2012-11-08 | 2016-07-29 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and / or responses to IFN? |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| JP2015014960A (en) | 2013-07-05 | 2015-01-22 | ソニー株式会社 | Information processor and storage medium |
| EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| EP3226848A4 (en) | 2014-12-03 | 2019-04-03 | Phio Pharmaceuticals Corp. | Methods for the treatment of alopecia areata utilizing gene modulation approaches |
| EA035899B1 (en) * | 2015-11-26 | 2020-08-28 | Новартис Аг | Diamino pyridine derivatives as jak inhibitors |
-
2016
- 2016-11-24 EA EA201891258A patent/EA035899B1/en not_active IP Right Cessation
- 2016-11-24 US US15/778,783 patent/US10570096B2/en active Active
- 2016-11-24 ES ES16805218T patent/ES2829052T3/en active Active
- 2016-11-24 KR KR1020187014470A patent/KR102097878B1/en active IP Right Grant
- 2016-11-24 WO PCT/IB2016/057105 patent/WO2017089985A1/en active Application Filing
- 2016-11-24 EP EP16805218.1A patent/EP3380465B1/en active Active
- 2016-11-24 SG SG11201803760VA patent/SG11201803760VA/en unknown
- 2016-11-24 CN CN201680065351.8A patent/CN108349937B/en active Active
- 2016-11-24 BR BR112018009540A patent/BR112018009540A2/en not_active Application Discontinuation
- 2016-11-24 EP EP20185507.9A patent/EP3757097B1/en active Active
- 2016-11-24 CU CU2018000044A patent/CU24506B1/en unknown
- 2016-11-24 PL PL20185507.9T patent/PL3757097T3/en unknown
- 2016-11-24 PE PE2018001004A patent/PE20181071A1/en unknown
- 2016-11-24 MX MX2018006495A patent/MX2018006495A/en unknown
- 2016-11-24 CR CR20180285A patent/CR20180285A/en unknown
- 2016-11-24 DK DK16805218.1T patent/DK3380465T3/en active
- 2016-11-24 LT LTEP16805218.1T patent/LT3380465T/en unknown
- 2016-11-24 PT PT168052181T patent/PT3380465T/en unknown
- 2016-11-24 AU AU2016359438A patent/AU2016359438B2/en not_active Ceased
- 2016-11-24 PT PT201855079T patent/PT3757097T/en unknown
- 2016-11-24 ES ES20185507T patent/ES2916582T3/en active Active
- 2016-11-24 MY MYPI2018701770A patent/MY195905A/en unknown
- 2016-11-24 CN CN202110135667.2A patent/CN112851578A/en not_active Withdrawn
- 2016-11-24 HU HUE16805218A patent/HUE052345T2/en unknown
- 2016-11-24 SI SI201630959T patent/SI3380465T1/en unknown
- 2016-11-24 RU RU2018122953A patent/RU2730007C2/en active
- 2016-11-24 PL PL16805218T patent/PL3380465T3/en unknown
- 2016-11-24 CA CA3005159A patent/CA3005159A1/en not_active Abandoned
- 2016-11-24 RS RS20201234A patent/RS60946B1/en unknown
- 2016-11-24 RU RU2020124922A patent/RU2020124922A/en unknown
- 2016-11-24 JP JP2018527091A patent/JP6634157B2/en not_active Expired - Fee Related
-
2018
- 2018-05-14 IL IL259360A patent/IL259360B/en active IP Right Grant
- 2018-05-15 PH PH12018501019A patent/PH12018501019A1/en unknown
- 2018-05-21 DO DO2018000127A patent/DOP2018000127A/en unknown
- 2018-05-22 CO CONC2018/0005354A patent/CO2018005354A2/en unknown
- 2018-05-22 CL CL2018001370A patent/CL2018001370A1/en unknown
- 2018-05-23 SA SA518391657A patent/SA518391657B1/en unknown
- 2018-05-31 EC ECIEPI201841731A patent/ECSP18041731A/en unknown
- 2018-10-05 HK HK18112730.0A patent/HK1253530A1/en unknown
-
2020
- 2020-01-08 US US16/737,366 patent/US11274080B2/en active Active
- 2020-10-14 HR HRP20201662TT patent/HRP20201662T1/en unknown
- 2020-11-03 CY CY20201101039T patent/CY1123543T1/en unknown
-
2022
- 2022-02-22 US US17/677,538 patent/US20220177432A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201811221XA (en) | Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |